IL102848A - Polypeptides having growth hormone releasing activity, their use and pharmaceutical compositions containing them - Google Patents

Polypeptides having growth hormone releasing activity, their use and pharmaceutical compositions containing them

Info

Publication number: IL102848A
Authority: IL; Israel
Prior art keywords: phe; ala; tyr; dala; dphe
Prior art date: 1991-08-22

Application number

IL102848A

Other languages

English (en)

Other versions

IL102848A0 (en

Original Assignee

Tulane Medical School

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-22

Filing date

1992-08-18

Publication date

1998-04-05

1992-08-18 Application filed by Tulane Medical School filed Critical Tulane Medical School

1993-01-31 Publication of IL102848A0 publication Critical patent/IL102848A0/xx

1998-04-05 Publication of IL102848A publication Critical patent/IL102848A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 133
102000018997 Growth Hormone Human genes 0.000 title claims abstract description 107
108010051696 Growth Hormone Proteins 0.000 title claims abstract description 107
239000000122 growth hormone Substances 0.000 title claims abstract description 107
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 80
229920001184 polypeptide Polymers 0.000 title claims description 54
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
230000003578 releasing effect Effects 0.000 title description 30
241001465754 Metazoa Species 0.000 claims abstract description 35
150000001875 compounds Chemical class 0.000 claims description 62
125000000217 alkyl group Chemical group 0.000 claims description 41
238000000034 method Methods 0.000 claims description 34
210000002966 serum Anatomy 0.000 claims description 28
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 25
210000004369 blood Anatomy 0.000 claims description 20
239000008280 blood Substances 0.000 claims description 20
-1 His Chemical compound 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 16
230000001737 promoting effect Effects 0.000 claims description 15
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 11
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 10
239000005556 hormone Substances 0.000 claims description 10
229940088597 hormone Drugs 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
230000002195 synergetic effect Effects 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 7
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 5
239000003488 releasing hormone Substances 0.000 claims description 5
XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 claims description 4
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 claims description 4
210000000577 adipose tissue Anatomy 0.000 claims description 4
108010070944 alanylhistidine Proteins 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 4
230000003247 decreasing effect Effects 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 claims description 4
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 3
101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 claims description 3
102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
108010034602 l-phenylalanyl sarcosine Proteins 0.000 claims description 3
210000003205 muscle Anatomy 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 2
FHZPGIUBXYVUOY-VWGYHWLBSA-N Dermorphin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)C1=CC=C(O)C=C1 FHZPGIUBXYVUOY-VWGYHWLBSA-N 0.000 claims description 2
206010013883 Dwarfism Diseases 0.000 claims description 2
108010010234 HDL Lipoproteins Proteins 0.000 claims description 2
102000015779 HDL Lipoproteins Human genes 0.000 claims description 2
108010007622 LDL Lipoproteins Proteins 0.000 claims description 2
102000007330 LDL Lipoproteins Human genes 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
239000000556 agonist Substances 0.000 claims description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 2
230000001684 chronic effect Effects 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
230000002267 hypothalamic effect Effects 0.000 claims description 2
150000002632 lipids Chemical class 0.000 claims description 2
208000003068 pituitary dwarfism Diseases 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
230000009467 reduction Effects 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
230000029663 wound healing Effects 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
230000015556 catabolic process Effects 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 48
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 34
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 30
229920005989 resin Polymers 0.000 description 28
239000011347 resin Substances 0.000 description 28
229910001868 water Inorganic materials 0.000 description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
241000282412 Homo Species 0.000 description 21
229940024606 amino acid Drugs 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 21
150000001413 amino acids Chemical class 0.000 description 19
239000007787 solid Substances 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000007792 addition Methods 0.000 description 16
235000019439 ethyl acetate Nutrition 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
241000700159 Rattus Species 0.000 description 15
239000000203 mixture Substances 0.000 description 14
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 11
125000006239 protecting group Chemical group 0.000 description 11
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
102000007079 Peptide Fragments Human genes 0.000 description 10
108010033276 Peptide Fragments Proteins 0.000 description 10
230000037396 body weight Effects 0.000 description 10
238000005859 coupling reaction Methods 0.000 description 10
238000003756 stirring Methods 0.000 description 10
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 9
239000008346 aqueous phase Substances 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 8
102100033367 Appetite-regulating hormone Human genes 0.000 description 8
101710119601 Growth hormone-releasing peptides Proteins 0.000 description 8
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
238000003127 radioimmunoassay Methods 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
230000008878 coupling Effects 0.000 description 7
238000010168 coupling process Methods 0.000 description 7
239000001257 hydrogen Substances 0.000 description 7
229960000208 pralmorelin Drugs 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
229910052786 argon Inorganic materials 0.000 description 6
239000012298 atmosphere Substances 0.000 description 6
239000007789 gas Substances 0.000 description 6
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000003828 vacuum filtration Methods 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 5
239000010410 layer Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
239000000126 substance Substances 0.000 description 5
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
239000002002 slurry Substances 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
238000010792 warming Methods 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
HKXLAGBDJVHRQG-YFKPBYRVSA-N L-lysinamide Chemical compound NCCCC[C@H](N)C(N)=O HKXLAGBDJVHRQG-YFKPBYRVSA-N 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
102100022831 Somatoliberin Human genes 0.000 description 3
101710142969 Somatoliberin Proteins 0.000 description 3
108010056088 Somatostatin Proteins 0.000 description 3
102000005157 Somatostatin Human genes 0.000 description 3
230000009102 absorption Effects 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
239000012300 argon atmosphere Substances 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutanoic acid Natural products NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
239000011521 glass Substances 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
230000021332 multicellular organism growth Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
229960001412 pentobarbital Drugs 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 3
229960000553 somatostatin Drugs 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
241000238424 Crustacea Species 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 2
101710202385 Growth hormone secretagogue receptor type 1 Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
101100270435 Mus musculus Arhgef12 gene Proteins 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010007568 Protamines Chemical class 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
239000012445 acidic reagent Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229960003767 alanine Drugs 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
229960005261 aspartic acid Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
238000006482 condensation reaction Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000010908 decantation Methods 0.000 description 2
KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000010265 fast atom bombardment Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 2
229940070765 laurate Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
229940049964 oleate Drugs 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
229940039748 oxalate Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
230000022558 protein metabolic process Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
229960001153 serine Drugs 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
229960004799 tryptophan Drugs 0.000 description 2
229960004441 tyrosine Drugs 0.000 description 2
229940070710 valerate Drugs 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
FOYXZVHDLXZETB-LBPRGKRZSA-N (2s)-2-(benzylazaniumyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound C([C@@H](C(=O)O)NCC=1C=CC=CC=1)C1=CNC=N1 FOYXZVHDLXZETB-LBPRGKRZSA-N 0.000 description 1
ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
240000005020 Acaciella glauca Species 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
125000002437 D-histidyl group Chemical group N[C@@H](C(=O)*)CC=1N=CNC1 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
UIRUVUUGUYCMBY-KCTSRDHCSA-N His-Trp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CN=CN3)N UIRUVUUGUYCMBY-KCTSRDHCSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-Histidine Natural products OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Natural products NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000020221 Short stature Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
108010056243 alanylalanine Proteins 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical class [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
CIHWJRSPVJBHGT-UHFFFAOYSA-N benzhydrylazanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(N)C1=CC=CC=C1 CIHWJRSPVJBHGT-UHFFFAOYSA-N 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
ORQXBVXKBGUSBA-UHFFFAOYSA-N cyclohexyl D-alanine Natural products OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000013100 final test Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 1
125000005487 naphthalate group Chemical group 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229960002429 proline Drugs 0.000 description 1
ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
239000004324 sodium propionate Substances 0.000 description 1
229960003212 sodium propionate Drugs 0.000 description 1
235000010334 sodium propionate Nutrition 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000005737 synergistic response Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229960004295 valine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Biophysics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

IL102848A 1991-08-22 1992-08-18 Polypeptides having growth hormone releasing activity, their use and pharmaceutical compositions containing them IL102848A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/748,350 US5663146A (en)	1991-08-22	1991-08-22	Polypeptide analogues having growth hormone releasing activity

Publications (2)

Publication Number	Publication Date
IL102848A0 IL102848A0 (en)	1993-01-31
IL102848A true IL102848A (en)	1998-04-05

Family

ID=25009088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL102848A IL102848A (en)	1991-08-22	1992-08-18	Polypeptides having growth hormone releasing activity, their use and pharmaceutical compositions containing them

Country Status (26)

Country	Link
US (2)	US5663146A (de)
EP (1)	EP0605484B1 (de)
JP (1)	JP3179489B2 (de)
KR (1)	KR100247212B1 (de)
CN (1)	CN1035256C (de)
AT (1)	ATE172742T1 (de)
AU (1)	AU666673B2 (de)
BG (1)	BG62655B1 (de)
BR (2)	BR9206398A (de)
CA (1)	CA2116120C (de)
CZ (1)	CZ293281B6 (de)
DE (1)	DE69227462T2 (de)
DK (1)	DK0605484T3 (de)
ES (1)	ES2124263T3 (de)
FI (2)	FI120095B (de)
HU (1)	HU223664B1 (de)
IL (1)	IL102848A (de)
MX (1)	MX9204861A (de)
NO (1)	NO314695B1 (de)
NZ (1)	NZ244034A (de)
PL (1)	PL169562B1 (de)
RO (1)	RO112507B1 (de)
RU (1)	RU2126014C1 (de)
SK (1)	SK282895B6 (de)
WO (1)	WO1993004081A1 (de)
ZA (1)	ZA926337B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5843941A (en)	1993-05-14	1998-12-01	Genentech, Inc.	Ras farnesyl transferase inhibitors
CA2179597A1 (en) *	1993-12-23	1995-06-29	Nils Langeland Johansen	Compounds with growth hormone releasing properties
US5854211A (en) *	1993-12-23	1998-12-29	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US20020111461A1 (en) *	1999-05-21	2002-08-15	Todd C. Somers	Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) *	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
HUP9802821A3 (en) *	1995-06-22	2000-03-28	Novo Nordisk As	Compounds with growth hormone releasing properties
WO1997040023A1 (en) *	1996-04-24	1997-10-30	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6127341A (en) *	1997-06-20	2000-10-03	Novo Nordisk A/S	Compounds with growth hormone releasing properties
WO1998058950A1 (en)	1997-06-20	1998-12-30	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
IL137007A0 (en)	1998-01-16	2001-06-14	Novo Nordisk As	Compounds with growth hormone releasing properties
WO1999039730A1 (en) *	1998-02-09	1999-08-12	Kaken Pharmaceutical Co., Ltd.	Oral preparations containing peptides promoting the secretion of growth hormone
US6919315B1 (en)	1998-06-30	2005-07-19	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6682908B1 (en)	1998-07-10	2004-01-27	Merck & Co., Inc.	Mouse growth hormone secretagogue receptor
WO2000002919A1 (en)	1998-07-13	2000-01-20	Merck & Co., Inc.	Growth hormone secretagogue related receptors and nucleic acids
JP2002522058A (ja)	1998-08-10	2002-07-23	メルク・アンド・カンパニー・インコーポレーテッド	イヌ成長ホルモン分泌促進物質受容体
EP1159292A2 (de) *	1998-08-14	2001-12-05	Administrators of The Tulane Educational Fund	Verbindungen mit wachstumshormonsbefreiender wirkung
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
US6696063B1 (en) *	1998-12-30	2004-02-24	Applied Research Systems Ars Holding N.V.	Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7022677B1 (en)	1999-02-18	2006-04-04	Kaken Pharmaceutical Co., Ltd.	Amide derivatives as growth hormone secretagogues
KR100699404B1 (ko) *	1999-02-18	2007-03-23	가켄 세야쿠 가부시키가이샤	성장 호르몬 분비촉진제로서의 신규 아미드 유도체
US6828331B1 (en) *	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
CN1367792A (zh) *	1999-06-25	2002-09-04	研究及应用科学协会股份有限公司	促生长素抑制素激动剂
CA2380058C (en) *	1999-07-23	2011-08-09	Kenji Kangawa	Novel peptides
US20040192593A1 (en)	1999-07-26	2004-09-30	Baylor College Of Medicine	Protease resistant ti-growth hormone releasing hormone
KR20020047096A (ko)	1999-07-26	2002-06-21	크로커 사무엘 에스	초활성 돼지 성장 호르몬 분비 호르몬 유사체
AU7685200A (en) *	1999-10-12	2001-04-23	Kaken Pharmaceutical Co., Ltd.	Powdery inhalational preparations and process for producing the same
UA73530C2 (uk)	1999-11-10	2005-08-15	Ново Нордіск А/С	Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) *	2000-05-29	2004-02-16	科研製薬株式会社	プラルモレリン含有点鼻用製剤
ATE446758T1 (de)	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US7855229B2 (en)	2000-08-24	2010-12-21	University Of Tennessee Research Foundation	Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en)	2000-08-24	2011-04-05	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en)	2000-08-24	2010-01-12	University Of Tennessee Research Foundation	Selective androgen receptor modulators and method of use thereof
CA2435563A1 (en)	2001-02-02	2002-08-15	Conjuchem Inc.	Long lasting growth hormone releasing factor derivatives
US7125840B2 (en) *	2001-10-09	2006-10-24	Eli Lilly And Company	Substituted dipeptides as growth hormone secretagogues
AU2002348417B9 (en) *	2001-10-26	2010-02-04	Baylor College Of Medicine	A composition and method to alter lean body mass and bone properties in a subject
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US20070066568A1 (en)	2005-08-31	2007-03-22	Dalton James T	Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US6831102B2 (en)	2001-12-07	2004-12-14	Bristol-Myers Squibb Company	Phenyl naphthol ligands for thyroid hormone receptor
AR037778A1 (es)	2001-12-11	2004-12-01	Advisys Inc	Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
US7015219B2 (en)	2001-12-19	2006-03-21	Bristol-Myers Squibb Company	3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
EP1499731B1 (de) *	2002-02-07	2011-05-25	Baylor College Of Medicine	Veränderte hirnanhangsdrüsenentwicklung in nachkommen von mit einer therapie mit wachstumshormon freisetzendem hormon behandelten trächtigen muttertieren
US7772433B2 (en)	2002-02-28	2010-08-10	University Of Tennessee Research Foundation	SARMS and method of use thereof
US7381730B2 (en)	2002-03-15	2008-06-03	Bristol-Myers Squibb Company	3-arylquinazoline derivatives as selective estrogen receptor beta modulators
AU2003220441A1 (en) *	2002-04-09	2003-10-27	Eli Lilly And Company	Dipeptidic growth hormone secretagogues
US20060167268A1 (en) *	2002-04-09	2006-07-27	Eli Lilly And Company, Patent Division,	Growth hormone secretagogues
WO2003094845A2 (en)	2002-05-08	2003-11-20	Bristol-Myers Squibb Company	Pyridine-based thyroid receptor ligands
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2004017986A1 (en)	2002-08-23	2004-03-04	Valorisation-Recherche, Societe En Commandite	Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
EP1567487A4 (de)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
US8309603B2 (en)	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
TW200504021A (en)	2003-01-24	2005-02-01	Bristol Myers Squibb Co	Substituted anilide ligands for the thyroid receptor
US20040204358A1 (en) *	2003-01-28	2004-10-14	Advisys, Inc.	Reducing culling in herd animals growth hormone releasing hormone (GHRH)
US7105537B2 (en)	2003-01-28	2006-09-12	Bristol-Myers Squibb Company	2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en)	2003-02-12	2007-04-17	Bristol-Myers Squibb Company	Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en)	2003-04-18	2009-07-07	Bristol-Myers Squibb Company	Thyroid receptor ligands
TW200424214A (en) *	2003-04-21	2004-11-16	Advisys Inc	Plasmid mediated GHRH supplementation for renal failures
US7459460B2 (en)	2003-05-28	2008-12-02	Bristol-Myers Squibb Company	Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7265145B2 (en)	2003-05-28	2007-09-04	Bristol-Myers Squibb Company	Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
CA2575926C (en) *	2003-08-04	2014-02-25	Advisys, Inc.	Canine specific growth hormone releasing hormone
AU2003272814A1 (en)	2003-10-02	2005-05-19	Ibrahim Al-Habdan	Peptide for promoting healing of fractures
CA2592891C (en)	2003-12-31	2013-05-28	Advisys, Inc.	Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
DE602005027661D1 (de) *	2004-01-20	2011-06-09	VGX Pharmaceuticals LLC	Isetzendem hormon (ghrh) aus muskelzellen durch speziesspezifisches signalpeptid
US20050164952A1 (en) *	2004-01-23	2005-07-28	Vital Pharmaceuticals, Inc.	Delivery system for growth hormone releasing peptides
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
JP2008507537A (ja) *	2004-07-23	2008-03-13	アドバイシーズ，インコーポレイテッド	予防接種レスポンスを増強する成長ホルモン放出ホルモン
CA2576915A1 (en)	2004-08-18	2006-03-02	Elixir Pharmaceuticals, Inc.	Growth-hormone secretagogues
US7456188B1 (en)	2005-04-28	2008-11-25	Bristol-Myers Squibb Company	C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2008006019A2 (en) *	2006-07-06	2008-01-10	Advisys Inc.	Growth hormone releasing hormone treatment to decrease cholesterol levels
ES2780193T3 (es)	2006-07-12	2020-08-24	Univ Tennessee Res Found	Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
BRPI0714725B1 (pt)	2006-08-02	2021-05-25	Cytokinetics, Inc	Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
US8299248B2 (en)	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US9844528B2 (en)	2006-08-24	2017-12-19	University Of Tennessee Research Foundation	SARMs and method of use thereof
US9730908B2 (en)	2006-08-24	2017-08-15	University Of Tennessee Research Foundation	SARMs and method of use thereof
US10010521B2 (en)	2006-08-24	2018-07-03	University Of Tennessee Research Foundation	SARMs and method of use thereof
AU2007287070C1 (en)	2006-08-24	2013-02-14	University Of Tennessee Research Foundation	Substituted acylanilides and methods of use thereof
ES2602789T3 (es)	2007-02-09	2017-02-22	Ocera Therapeutics, Inc.	Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
EP2155769B1 (de)	2007-05-04	2012-06-27	Katholieke Universiteit Leuven KU Leuven Research & Development	Schutz gegen gewebedegeneration
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
US8003689B2 (en)	2008-06-20	2011-08-23	Gtx, Inc.	Metabolites of selective androgen receptor modulators and methods of use thereof
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (de)	2010-04-23	2015-10-28	Cytokinetics, Inc.	Bestimmte aminopyrimidine und aminotriazine, zusammensetzungen daraus und verfahren zu ihrer verwendung
WO2013190520A2 (en)	2012-06-22	2013-12-27	The General Hospital Corporation	Gh-releasing agents in the treatment of vascular stenosis and associated conditions
EP3733170A1 (de)	2012-07-13	2020-11-04	Oncternal Therapeutics, Inc.	Verfahren zur behandlung von androgenrezeptor(ar)-positivem brustkrebs mit selektivem androgenrezeptormodulator (sarms)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US12685719B2 (en)	2012-07-13	2026-07-21	University Of Tennessee Research Foundation	Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
CA2889499C (en)	2012-10-24	2019-09-10	Daiichi Sankyo Company, Limited	Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
EP2983694B1 (de)	2013-04-08	2022-06-22	President and Fellows of Harvard College	Zusammensetzungen zur verjüngung von skelettmuskelstammzellen
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
EP3990447A1 (de)	2019-06-27	2022-05-04	Cytokinetics, Inc.	Polymorphe von 1-(2-(((trans)-3-fluor-1-(3-fluorpyridin-2-yl)butyl)methyl)amino) pyrimidin-5-yl)-1h-pyrrol-3-carboxamid
WO2023275715A1 (en)	2021-06-30	2023-01-05	Pfizer Inc.	Metabolites of selective androgen receptor modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4228156A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) *	1979-03-30	1980-09-16	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) *	1979-03-30	1980-10-07	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) *	1979-03-30	1980-09-16	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) *	1979-03-30	1980-09-16	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) *	1979-03-30	1980-09-23	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) *	1979-03-30	1984-10-09	Frank A. Momany	Synthetic peptides having pituitary growth hormone releasing activity
WO1983002272A1 (en) *	1981-12-28	1983-07-07	Beckman Instruments Inc	Synthetic peptides having pituitary growth hormone releasing activity
US4410513A (en) *	1981-12-28	1983-10-18	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) *	1981-12-28	1983-10-18	Beckman Instruments, Inc.	Combinations having synergistic pituitary growth hormone releasing activity
GB8314646D0 (en) *	1983-05-26	1983-06-29	Wellcome Found	Pharmaceutical amides
US4880778A (en) *	1986-05-12	1989-11-14	Eastman Kodak Company	Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) *	1987-06-12	1989-06-13	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
US4880777A (en) *	1987-09-01	1989-11-14	Eastman Kodak Company	Synthetic peptides having growth hormone releasing activity
AU628322B2 (en) *	1988-01-28	1992-09-17	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) *	1988-01-28	1993-05-27	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
WO1989010933A1 (en) *	1988-05-11	1989-11-16	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
US5486505A (en) *	1990-07-24	1996-01-23	Polygen Holding Corporation	Polypeptide compounds having growth hormone releasing activity
EP0540626A1 (de)	1990-07-24	1993-05-12	Eastman Chemical Company	Verfahren zur synthese von peptiden
IL98910A0 (en) *	1990-07-24	1992-07-15	Polygen Holding Corp	Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them

1991
- 1991-08-22 US US07/748,350 patent/US5663146A/en not_active Expired - Lifetime
1992
- 1992-08-18 IL IL102848A patent/IL102848A/en not_active IP Right Cessation
- 1992-08-20 EP EP92919262A patent/EP0605484B1/de not_active Expired - Lifetime
- 1992-08-20 ES ES92919262T patent/ES2124263T3/es not_active Expired - Lifetime
- 1992-08-20 JP JP50458593A patent/JP3179489B2/ja not_active Expired - Lifetime
- 1992-08-20 KR KR1019940700542A patent/KR100247212B1/ko not_active Expired - Fee Related
- 1992-08-20 HU HU9400495A patent/HU223664B1/hu not_active IP Right Cessation
- 1992-08-20 US US07/932,494 patent/US5776901A/en not_active Expired - Lifetime
- 1992-08-20 BR BR9206398A patent/BR9206398A/pt not_active Application Discontinuation
- 1992-08-20 PL PL92302434A patent/PL169562B1/pl not_active IP Right Cessation
- 1992-08-20 NZ NZ244034A patent/NZ244034A/en not_active IP Right Cessation
- 1992-08-20 CZ CZ1994400A patent/CZ293281B6/cs not_active IP Right Cessation
- 1992-08-20 RU RU94016393A patent/RU2126014C1/ru not_active IP Right Cessation
- 1992-08-20 SK SK204-94A patent/SK282895B6/sk not_active IP Right Cessation
- 1992-08-20 AT AT92919262T patent/ATE172742T1/de active
- 1992-08-20 WO PCT/US1992/007026 patent/WO1993004081A1/en not_active Ceased
- 1992-08-20 RO RO94-00256A patent/RO112507B1/ro unknown
- 1992-08-20 CA CA002116120A patent/CA2116120C/en not_active Expired - Lifetime
- 1992-08-20 DE DE69227462T patent/DE69227462T2/de not_active Expired - Lifetime
- 1992-08-20 DK DK92919262T patent/DK0605484T3/da active
- 1992-08-20 AU AU25416/92A patent/AU666673B2/en not_active Ceased
- 1992-08-21 ZA ZA926337A patent/ZA926337B/xx unknown
- 1992-08-21 MX MX9204861A patent/MX9204861A/es unknown
- 1992-08-22 CN CN92110868A patent/CN1035256C/zh not_active Expired - Fee Related
1994
- 1994-02-18 BG BG98489A patent/BG62655B1/bg unknown
- 1994-02-21 FI FI940807A patent/FI120095B/fi not_active IP Right Cessation
- 1994-02-21 NO NO19940592A patent/NO314695B1/no not_active IP Right Cessation
1997
- 1997-04-22 BR BR1100309-0A patent/BR1100309A/pt active IP Right Grant
2005
- 2005-05-02 FI FI20050467A patent/FI120691B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUT69178A (en)	1995-08-28
BR9206398A (pt)	1994-12-27
DK0605484T3 (da)	1999-07-05
SK20494A3 (en)	1994-10-05
CN1035256C (zh)	1997-06-25
SK282895B6 (sk)	2003-01-09
CZ293281B6 (cs)	2004-03-17
RO112507B1 (ro)	1997-10-30
ATE172742T1 (de)	1998-11-15
NZ244034A (en)	1995-08-28
DE69227462T2 (de)	1999-04-08
PL169562B1 (pl)	1996-08-30
AU2541692A (en)	1993-03-16
CZ40094A3 (en)	1994-11-16
FI120095B (fi)	2009-06-30
BR1100309A (pt)	2000-08-01
JP3179489B2 (ja)	2001-06-25
HU223664B1 (hu)	2004-11-29
WO1993004081A1 (en)	1993-03-04
NO940592D0 (no)	1994-02-21
EP0605484A1 (de)	1994-07-13
JPH07507039A (ja)	1995-08-03
ES2124263T3 (es)	1999-02-01
US5663146A (en)	1997-09-02
EP0605484B1 (de)	1998-10-28
CA2116120A1 (en)	1993-02-23
NO314695B1 (no)	2003-05-05
BG98489A (bg)	1995-02-28
ZA926337B (en)	1993-04-22
FI940807A0 (fi)	1994-02-21
DE69227462D1 (de)	1998-12-03
MX9204861A (es)	1994-06-30
FI940807L (fi)	1994-02-21
FI20050467L (fi)	2005-05-02
IL102848A0 (en)	1993-01-31
US5776901A (en)	1998-07-07
CN1073684A (zh)	1993-06-30
KR100247212B1 (ko)	2000-03-15
AU666673B2 (en)	1996-02-22
CA2116120C (en)	2002-12-03
FI120691B (fi)	2010-01-29
BG62655B1 (bg)	2000-04-28
NO940592L (no)	1994-04-14
RU2126014C1 (ru)	1999-02-10
HU9400495D0 (en)	1994-05-30

Legal Events

Date	Code	Title
1998-10-30	FF	Patent granted
1998-12-27	KB	Patent renewed
2001-06-14	RH	Patent void
2002-09-12	KB	Patent renewed
2006-10-04	KB	Patent renewed
2010-11-30	KB	Patent renewed
2013-04-30	EXP	Patent expired